enVVeno Medical Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVNO research report →
Price Chart
About the company
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency.
- CEO
- Robert A. Berman
- IPO
- 2018
- Employees
- 33
- HQ
- Irvine, CA, US
Get TickerSpark's AI analysis on NVNO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.65M
- P/E
- -0.02
- PEG
- -0.00
- P/S
- 0.00
- P/B
- 0.23
- EV/EBITDA
- -0.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -70.33%
- ROIC
- -94.78%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+100.0%
- Op Income
- $-20,899,000
- Net Income
- $-19,472,000+10.8%
- EPS
- $-33.06+97.9%
- OCF Growth
- +7.5%
- FCF Growth
- +7.7%
- 52W High
- $14.89
- 52W Low
- $5.22
- 50D MA
- $7.67
- 200D MA
- $9.99
- Beta
- 1.07
- RSI (14)
- 27
- Avg Volume
- 29.69K
No earnings-call transcripts are available for NVNO yet.
- Free Float
- 91.9%
- Shares Outstanding
- 694.83K
- Float Shares
- 638.25K
of shares held by institutions
17 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 299.25K | ▼ 561.95K |
| Kingdon Capital Management, L.L.C. | 36.17K | 0 |
| Cm Management, LLC | 17.14K | ▼ 18.57K |
| Citadel Advisors LLC | 15.31K | ▲ 15.31K |
| Two Sigma Advisers, LP | 14.00K | ▲ 14.00K |
| Vanguard Capital Management LLC | 6.29K | 0 |
| Jpmorgan Chase & Co | 5.22K | ▲ 11 |
| Vanguard Fiduciary Trust Co | 2.18K | 0 |
| Ubs Group AG | 1.97K | ▲ 1.96K |
| Westside Investment Management, Inc. | 1.52K | 0 |
| Cibc Private Wealth Group LLC | 860 | 0 |
| Tower Research Capital LLC (Trc) | 580 | ▲ 249 |
Held by 8 ETFs
Biggest fund positions in NVNO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 11, 26 | Duhay Francis | sell | 11 |
| Jun 11, 26 | Duhay Francis | sell | 140 |
| Mar 12, 26 | Duhay Francis | sell | 140 |
| Dec 16, 25 | BERMAN ROBERT ANDREW | other | 200,000 |
| Dec 16, 25 | Alavi Hamed | other | 50,000 |
| Dec 16, 25 | Glickman Marc H. | other | 100,000 |
| Dec 11, 25 | Duhay Francis | other | 135,883 |
| Dec 11, 25 | Gray Robert | other | 135,883 |
| Dec 11, 25 | Jenusaitis Matthew | other | 135,883 |
| Dec 11, 25 | Shrivastava Sanjay | other | 135,883 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our NVNO coverage
Recent articles, reports, and earnings notes.
No research on NVNO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate NVNO report →enVVeno Medical's First-in-Class enVVe System to Be Featured at The VEINS 2026 Innovation Summit as Company Advances Toward U.S. Pivotal Trial
accessnewswire.com · Oct 2
enVVeno Medical Presentation from H.C. Wainwright Conference Now Available On-Demand
accessnewswire.com · Sep 11
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
accessnewswire.com · Aug 27
Independent Health Economic Study Recently Published in Journal of Vascular Surgery Reports Economic Dominance of enVVeno Medical's Replacement Venous Valve Therapy Compared to Standard of Care Treatments
accessnewswire.com · Aug 4
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
accessnewswire.com · Jul 31
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
accessnewswire.com · Jul 15
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
accessnewswire.com · Jul 7
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
accessnewswire.com · Jun 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.